ROPARK XL 1MG contains Ropinirole which belongs to the group of medicines called dopamine agonists. It is used to treat Parkinson’s disease in adult patients. Parkinson’s disease is a progressive neuro-degenerative disorder, that predominately affects the dopamine-producing neurons in the brain. It is characterized by rigidity, tremor, defective posture and gait and drooling with or without dementia.
Generally, patients with Parkinson’s disease would have low levels of dopamine in some parts of their brains. Ropinirole acts similar to that of natural dopamine in the brain and helps in the reduction of symptoms of Parkinson’s disease. ROPARK XL 1MG can be taken alone or in combination with L-DOPA to achieve best results. Avoid smoking and consumption of alcohol while taking this medicine, because it may increase the risk of side effects.
While taking this medicine, inform your doctor if you experience any unusual behaviours (such as an unusual urge to gamble, drive or temptation to carry out certain activities that could harm yourself or others excessive eating or spending or increased sexual urges). After stopping or reducing the dose of ropinirole, inform your doctor if you experience any withdrawal symptoms such as depression, apathy, anxiety, fatigue, sweating or pain. Your doctor would suggest a suitable additional or alternative treatment for you.
The most common side effect of this medicine includes dizziness, drowsiness, feeling tired, nausea, vomiting or stomach pain. Contact your doctor if any of the symptoms bothers you. Before taking this medicine, inform your doctor if you have any kidney, liver or heart disease. ROPARK XL 1MG is not recommended for use in pregnant or breastfeeding women and in children and adolescents under 18 years of age. Consult your doctor before taking.
Dopamine is a chemical messenger that is required for controlling body movements (motor activity) in the brain. Ropinirole has neurological effects similar to that of natural dopamine. Stimulation of dopamine receptors by ropinirole improves motor function which helps in the reduction of symptoms of Parkinson’s disease.
Take ROPARK XL 1MG once daily at the same time each day or as directed by your physician. Swallow the medicine as whole with plenty of water. Do not crush or chew the medicine as it may result in overdosage. Your doctor will decide the correct dose and duration for you depending upon your age, body weight and body condition.
If you are switching from ropinirole immediate-release tablets to ROPARK XL 1MG, take your ropinirole immediate-release tablets normally, the day before you switch and take this medicine on the next day. Continue to take this medicine, as long as your doctor tells you to do so, to obtain better results.
Nausea or vomiting:
Try taking this medicine with, or just after meals. Stick to simple meals. Do not eat rich or spicy food.
Stomach pain:
Try to rest and relax. You can eat and drink slowly or have smaller and frequent meals. Keeping a heat pad on your stomach may also help. If still pain persists, speak to your doctor.
Feeling tired, dizzy or drowsy:
Try to rest and relax. Get enough sleep. Avoid travelling, driving vehicles or operating any machinery while you are feeling tired or dizzy.
ROPARK XL 1MG should be used with caution in pregnant women. Consult your doctor before taking this medicine.
ROPARK XL 1MG should be used with caution in breastfeeding women. Consult your doctor before taking this medicine.
Do not drive or operate any machines, because this medicine may make you feel extremely drowsy.
Avoid consumption of alcohol while taking this medicine.
ROPARK XL 1MG is not recommended for use in patients with severe kidney disease. Consult your doctor for advice.
ROPARK XL 1MG is not recommended for use in patients with severe liver disease. Consult your doctor for advice.
Do not take ROPARK XL 1MG if you are allergic (hypersensitive) to Ropirinole or any other ingredients in this medicine.
ROPARK XL 1MG should be used with caution in patients having serious heart problems. Consult your doctor for advice before taking.
Talk to your doctor, if you are taking,
Drug | : | Ropinirole |
Pharmacological Category | : | Dopamine agonist, Anti-Parkinson drugs |
Therapeutic Indication | : | Parkinson’s disease, Restless Legs Syndrome |
Dosage Forms | : | Tablet |
Store below 20-25°C and keep out of reach of children.
Can we stop taking ROPARK XL 1MG abruptly?
No. Do not stop taking this medicine, without consulting your doctor because it may lead to unpleasant withdrawal symptoms. Continue to take this medicine, as long as your doctor tells you to do so, to obtain better results.
Can ROPARK XL 1MG make RLS worse?
Yes. The most common side effect of this medicine is worsening of RLS. You might feel that your symptoms started more earlier than usual or be more intense or affect other previously unaffected limbs. Contact your doctor if this symptom bothers you.
Can ROPARK XL 1MG cause insomnia?
Yes. It can cause insomnia in some individuals, although not everybody gets them. Contact your doctor if this symptom bothers you.
Can ROPARK XL 1MG cause hallucination?
Yes. It can cause hallucinations in some individuals. Contact your doctor if this symptom bothers you.
1. KD. Tripathi. Antiparkinsonian Drugs. Essentials of medical pharmacology. Seventh edition. 2013. Page – 430-431.
2. Elaine Sanders-Bush and Lisa Hazelwood. 5-Hydroxytryptamine (serotonin) and dopamine. Goodman & Gilman’s: The Pharmacological basics of Therapeutics. 12th Edition. New York McGraw Hill Medical 2011. Page – 358.
3. David G. Standaert and Erik D. Roberson. Treatment of Central Nervous System Degenerative disorders. Goodman & Gilman’s: The Pharmacological basics of Therapeutics. 12th Edition. New York McGraw Hill Medical 2011. Page – 616-617.
4. Gerald G. Briggs and Roger K. Freeman. R. A reference guide to fetal and neonatal risk: Drugs in Pregnancy and Lactation. Tenth Edition. 2015. Page – 3455-3456.
5. GlaxoSmithKline. REQUIP (Ropinirole Hydrochloride) IR Long-Term Phase 4 Study. NIH U.S. National Library of Medicine ClinicalTrials.gov. [Revised on December 2010] [Accessed 4th December 2020] https://clinicaltrials.gov/ct2/show/NCT00485069
6. Actavis Ltd, BLB016. Electronic Medicines Compendium (EMC). [Revised on June 2020] [Accessed 8th December 2020] https://www.medicines.org.uk/emc/files/pil.729.pdf
7. Pharmathen SA or Pharmathen International SA. Electronic Medicines Compendium (EMC). [Revised on June 2020] [Accessed 8th December 2020] https://www.medicines.org.uk/emc/files/pil.5335.pdf
8. Birmingham, Sandwell, Solihull and environs Area Prescribing Committee (BSSE APC). Ropinirole Immediate Release (IR) and Modified Release (MR) ESCA. [Revised on July 2018] [Accessed 8th December 2020] http://www.birminghamandsurroundsformulary.nhs.uk/docs/esca/BSSE%20APC%20ESCA%20Ropinirole%20IR%20and%20MR%20for%20PD.pdf?uid=782173289&uid2=201582113185253&UNLID=128465690201811610558
The contents of this website are for informational purposes only and not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition. Do not disregard professional medical advice or delay in seeking it because of something you have read on this website.